English
Specials
    Upgrade
    MoneycontrolBe a PRO
    Moneycontrol PRO
    Open App
    you are here: HomeNewsBusinessMoneycontrol Research

    Sun Pharma’s steady India business and US speciality portfolio should help it do well in FY22

    What adds to the Sun Pharma's investment case is the prospect for US specialty. The management hopes to achieve EBITDA break-even for a few products next fiscal

    Anubhav Sahu
    August 03, 2020 / 01:35 PM IST
    Sun Pharma’s steady India business and US speciality portfolio should help it do well in FY22

    Revlimid is a blockbuster blood cancer drug with sales of $12.1 billion for BMS in 2020.

    PRO Only Highlights
    -      Quarterly performance largely backed by improved realisations
    -      Medium-term triggers China plus and protectionist measures for tyre industry
    -      Valuations not inexpensive; but improved medium-term outlook

    Anubhav Sahu Moneycontrol Research Highlights - June quarter sales helped by domestic market and API performance - Improved margins may not be sustained in near term - A few specialty products to break even next fiscal - Valuation expensive; to benefit from sector wide rally India’s largest pharma company Sun Pharma (CMP: Rs 531 Market cap: Rs 127,573 crore) is seeing a technical break-out, post its June quarter results. Interestingly, a huge one-time exceptional charge has not curbed investors’ enthusiasm, while the improved margins have helped. Let’s have a closer...

    • PRO Panorama

      Moneycontrol Pro Panorama | The case for a 50-bps rate hike

      Sep 26, 2022 / 03:13 PM IST

      In today’s edition of Moneycontrol Pro Panorama: RBI's liquidity problem, Telecom draft bill needs rectification, plummeting Hang Seng raises China's concerns, India's road sector in quandary, and more

      Read Now
    • PRO Weekender

      Moneycontrol Pro Weekender | Fighting the Fed 

      Sep 3, 2022 / 10:06 AM IST

      India is bracing for the ripple effect of the frontloading of rate hikes by the US Fed. The question is, can it have the last laugh

      Read Now

    To read the full story, Subscribe to Moneycontrol PRO

    Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

    View Plans

    Already a member? Sign in

    Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

    50% OFF

    What Do You Get

    • Ad free experience

      Experience a non-intrusive navigation and faster response in the ad free mode

    • Sharpest Opinions

      Access to 230+ exclusive stories per month from our editorial and Experts

    • +

      Have a Global edge with access to content from world renowned experts and journalist

    • Actionable Insights

      Access to 40+ weekly investment ideas including 4 daily technical calls

    • Virtual Events

      Exclusive access to live webinars from market experts on trading and investment strategies

    • Newsletters

      Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

    View Offers

    Get upto 50% discount on limited period offers